Current therapy and drug resistance in metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Published:2023-05 Issue: Volume:68 Page:100962
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Cai Maoping,Song Xian-Lu,Li Xin-An,Chen Mingkun,Guo Jiading,Yang Dong-Hua,Chen Zhanghui,Zhao Shan-Chao

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference126 articles.

1. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration;Abida;J. Clin. Oncol.,2020

2. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer;Annala;Cancer Discov.,2018

3. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study;Antonarakis;J. Clin. Oncol.,2020

4. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade;Arora;Cell,2013

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circular RNA hsa_circ_0001610 promotes prostate cancer progression by sponging miR-1324 and upregulating PTK6;Gene;2024-12

2. ELAVL1 regulates PD-L1 mRNA stability to disrupt the infiltration of CD4-positive T cells in prostate cancer;Neoplasia;2024-11

3. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

4. Identification of circadian clock-related immunological prognostic index and molecular subtypes in prostate cancer;Discover Oncology;2024-09-11

5. Potential drug targets for prostate cancer ： A mendelian randomization study and application for target-derived drug design;2024-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3